Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX5 | P09917 | 2/20 | 0.48 |
| ▸ | ESR1 | P03372 | 2/20 | 0.47 |
| ▸ | ESR2 | Q92731 | 2/20 | 0.47 |
| ▸ | ASIC3 | Q9UHC3 | 1/20 | 0.44 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.43 |
| ▸ | NOS1 | P29475 | 9/20 | 0.39 |
| ▸ | NOS3 | P29474 | 5/20 | 0.39 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.38 |
| ▸ | LARS1 | Q9P2J5 | 1/20 | 0.37 |
| ▸ | BRS3 | P32247 | 1/20 | 0.37 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.36 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8096636 | 0.79 | GABRA1 (0.59) | ALOX5ESR1ESR2ASIC3PDPK1 | |
| SCHEMBL6702831 | 0.77 | NOS1 (0.39) | ASIC3PDPK1NOS1NOS3IRAK4 | |
| SCHEMBL5127450 | 0.76 | ALOX5 (0.68) | ALOX5ESR1ESR2GABRA1GABRB2 | |
| SCHEMBL30250904 | 0.76 | ALOX5 (0.68) | ALOX5ESR1ESR2GABRA1GABRB2 | |
| SCHEMBL6585551 | 0.75 | NOS1 (0.60) | ALOX5NOS1NOS3GABRA1GABRB2 | |
| SCHEMBL7073864 | 0.74 | NOS1 (0.47) | NOS1NOS3GABRA1GABRB2 | |
| SCHEMBL8082378 | 0.74 | NOS1 (0.57) | NOS1NOS3 | |
| SCHEMBL1023623 | 0.72 | ALOX5 (0.58) | ALOX5ESR1ESR2GABRA1GABRB2 | |
| SCHEMBL7078300 | 0.71 | NOS1 (0.38) | NOS1NOS3 | |
| SCHEMBL9198775 | 0.70 | ALOX5 (0.60) | ALOX5ESR1ESR2GABRA1GABRB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040229911-A1 | New pharmaceutical combinations for NOS inhibitors | PFIZER INC | 2004-11-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040229911-A1 | New pharmaceutical combinations for NOS inhibitors | NOS1, NOS3, NPBWR1 | ALOX5 1646/4885ESR1 3310/4885ESR2 2398/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.